[Management of acute ischemic stroke].
Minematsu
Kazuo
K
Cerebrovascular Division, Department of Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita-shi, Osaka 565-8565, Japan.
D000077284:Abciximab; D000721:Ancrod / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy*; D019983:Guideline Adherence; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D013300:Streptokinase; D000721:Ancrod; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase; D000077284:Abciximab